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Objective: A role for childhood adversity in the development of numerous medical conditions in adults
has been described in the general population, but has not been examined in patients with bipolar
disorder who have multiple medical comorbidities which contribute to their premature mortality.
Methods: More than 900 outpatients (average age 41) with bipolar disorder completed questionnaires
that included information about the occurrence of verbal, physical, or sexual abuse in childhood and
whether their parents had a mood or substance abuse disorder, or a history of suicidality. These factors
were combined to form a total childhood adversity score, which was then related to one or more of 30
medical conditions patients rated as present or absent.
Results: The child adversity score was signiﬁcantly related to the total number of medical comorbidities
a patient had (po .001), as well as to 11 speciﬁc medical conditions that could be modeled in a logistic
regression (po .03). These included: asthma, arthritis, allergies, chronic fatigue syndrome, chronic
menstrual irregularities, ﬁbromyalgia, head injury (without loss of consciousness), hypertension,
hypotension, irritable bowel syndrome, and migraine headaches.
Limitations: The contribution of parental diagnosis to childhood adversity is highly inferential.
Conclusions: These data link childhood adversity to the later occurrence of multiple medical conditions
in adult outpatients with bipolar disorder. Recognition of these relationships and early treatment
intervention may help avert a more severe course of not only bipolar disorder but also of its prominent
medical comorbidities and their combined adverse effects on patients’health, wellbeing, and longevity.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Bipolar disorder is associated with a host of psychiatric and
medical comorbidities (Jerrell et al., 2010). These comorbidities
have a dramatic effect on behavior, functioning, and longevity.
Recent estimates suggest that bipolar disorder, like other major
mental disorders, is associated with a marked reduction in years of
life expectancy (Osby et al., 2001). In the U.S. these range from 13
years of lost life expectancy in some eastern states such as Virginiall rights reserved.
þ301 530 8247.
kerbcn@gmail.com,to 30 years in some western states (Colton and Manderscheid,
2006; Newcomer and Hennekens, 2007). While suicide is a factor,
medical causes and contributions appear to exert the major effect
(Colton and Manderscheid, 2006; Newcomer and Hennekens, 2007;
Osby et al., 2001), especially cardiovascular diseases. The presence
of childhood adversity appears to exert a negative inﬂuence on the
earlier onset and adverse course of bipolar disorder (Brown et al.,
2005; Garno et al., 2005; Leverich et al., 2002). Whether it also
exerts an inﬂuence on increased risk for medical comorbidities
remains to be studied.
In general medical practices, a history of childhood abuse or
neglect is associated with a signiﬁcant increase in the onset of a
variety of medical illnesses, some of which appear predominantly
in adulthood (Anda et al., 2006, 2008, 2010; Dube et al., 2009;
R.M. Post et al. / Journal of Affective Disorders 147 (2013) 288–294 289Felitti et al., 1998; Shonkoff and Garner, 2012; Wolkowitz et al.,
2011). These include: obesity, cancer, stroke, COPD, diabetes,
fractures, hepatitis, asthma, headaches, pulmonary disease, and
autoimmune disorders, in addition to overall worse health and
functional disability (Anda et al., 2009; Walker et al., 1999).
Some of the potential mechanisms of these long-term effects
have been revealed in preclinical and clinical studies. In the
laboratory, early adversity can be associated with lifelong reduc-
tions of BDNF in frontal cortex and hippocampus (Post, 2007;
Roceri et al., 2004; Roth et al., 2009), decreases in the set-point for
neurogenesis (Gould and Tanapat, 1999), increases in inﬂamma-
tory cytokines, and evidence of endocrine and behavioral over-
reactivity (Champagne and Meaney, 2001; Plotsky et al., 2005;
Weaver et al., 2004). Many of these abnormalities have also been
documented in human populations exposed to a variety of types
of childhood adversity (Dube et al., 2009; Heim et al., 2004;
Kauer-Sant’Anna et al., 2007; McGowan et al., 2009).
In this manuscript we explore the relationship of childhood
adversity to the occurrence of medical comorbidities in bipolar
disorder (Jerrell et al., 2010; McElroy et al., 2001; Osby et al.,
2001) and postulate that childhood adversity is a risk factor for
the development of a range of subsequent medical comorbidities
reported by adult outpatients.Table 1
Frequency of comorbidities in bipolar patients: association with higher tCAS.










Allergies 949 353 37.2 4.66 3.31
Arthritis 946 125 13.2 5.23 3.6
Asthma 947 122 12.9 5.03 3.64
Cancer 948 24 2.5 4.63 3.8
Chronic fatigue syndrome 949 58 6.1 5.41 3.72
Chronic menstrual
irregularities (no male)
505 140 27.7 5.11 3.79
Diabetes 949 30 3.2 3.89 3.81
Fibromyalgia 947 29 3.1 5.89 3.75
Head injury (with loss of
consciousness)
949 134 14.1 4.4 3.72
Head injury (without loss of
consciousness)
950 209 22.0 5.81 3.52
Heart disease 949 55 5.8 4.28 3.78
Hypertension (high blood
pressure)
953 152 15.9 4.28 3.78
Hyperthyroidism 945 38 4.0 3.5 3.84
Hypoglycemia 952 60 6.3 4.84 3.75
Hypotension
(low blood pressure)
952 100 10.5 5.12 3.67
Hypothyroidism 946 142 15.0 4.01 3.79
Irritable bowel syndrome 944 127 13.5 5.15 3.6
Kidney disease 949 29 3.1 3.76 3.82
Liver disease/Hepatitis 950 43 4.5 5.26 3.75
Migraine headache 950 228 24.0 4.94 3.45
other 721 95 13.2 4.09 3.7
Seizure 946 31 3.3 5.63 3.75
This table lists the frequency with which each comorbidity was found in our
patient population as well as the mean tCAS for patients with (present) and
without (absent) that comorbidity. Encephalitis, hyperadrenalism (Cushing’s
disease), hypoadrenalism (Addison’s disease), meningitis, multiple sclerosis,
narcolepsy, Parkinson’s disease, and stroke were also queried, but the incidence
was less then 2%, and they were not listed in the table or further examined.2. Methods
The demographics and clinical characteristics of the outpati-
ents in the former Stanley Foundation Bipolar Treatment Out-
come Network, now continuing as the Bipolar Collaborative
Network, have been previously detailed (Post et al., 2010a,
2010b, 2001). Brieﬂy, outpatients with Bipolar I, II or schizoaffec-
tive disorder, bipolar type, were recruited from four academic
sites in the U.S. and three in The Netherlands and Germany. They
gave informed consent for detailed documentation of their prior
course of illness and prospective evaluation during naturalistic
treatment.
The Network recruited over 900 patients from 1995 to 2002
whose diagnoses were validated by SCID interview and conﬁrmed
in prospective longitudinal assessments. Participants were excluded
only for active substance abuse requiring acute treatment in
another setting, or major medical illnesses that would preclude
participation in clinical drug treatment evaluations. Upon admis-
sion to the Network, patients ﬁlled out a detailed patient ques-
tionnaire on demographics and course of illness variables that
included questions on the occurrence and frequency of physical,
sexual, or verbal abuse in childhood; family history of psychiatric
disorders; and a personal history of medical conditions.
In medical populations, Felitti et al. (1998) and Anda et al.
(2006) utilized an index of total Adverse Childhood Experiences
(ACE) that included the presence or absence of abuse and also a
positive parental history of psychiatric disorders including alcohol
and substance abuse. In our study, we similarly used a total
childhood adversity score (tCAS) which included assessments of
childhood physical, sexual, or verbal abuse as well as parental
psychiatric difﬁculties. Childhood physical, sexual, or verbal abuse
each were scored on a 0–3 scale according to their reported
frequency of occurrence (for a maximum score of 9). History of
parental psychiatric difﬁculties was scored as 0,1, or 2, depending
on whether neither, one, or both parents had these difﬁculties. A
report of an ‘‘absent’’ or ‘‘not likely’’ diagnosis was scored as a 0,
while a ‘‘likely’’ or ‘‘deﬁnite’’ rating in the patient questionnaire
was scored as present for that parent. Parental history was
assessed for the presence of an affective disorder (either unipolar
or bipolar); drug abuse; alcohol abuse; and the occurrence of a
suicide or major suicide attempt. The maximum score was 8 ifboth parents were positive for these psychiatric difﬁculties,
yielding a maximum total childhood adversity score (tCAS) of 17.
We then examined the relationship of the tCAS to the patients’
report of the lifetime occurrence of 30 medical conditions, each
was scored as present if the patient rated it as ‘‘likely’’ or
‘‘deﬁnite’’ having that condition, and absent if it was scored as
‘‘unlikely’’ or ‘‘not present’’. These medical conditions were
tabulated for the 968 patients who completed the patient ques-
tionnaire. If the comorbidity was rare, (i.e., occurring in less than
20 patients), it was dropped from the analysis in this study due to
insufﬁcient sample size. The tCAS scores were then compared in
the bipolar subjects as a function of the presence or absence of
each of the remaining medical conditions. For this calculation we
used tCAS scores only for those 904 who answered all of the
questions related to childhood adversity burden. The mean tCAS
score was 3.7473.26 for all 968 patients, while it was 3.8473.27
for the 904 patients answering all questions.
The relationship between the tCAS and each patient’s total
number of comorbidities was also examined with a multinomial
logistic regression with each patient having none (0), few (1–3), or
many (4þ) comorbidities using the few category as the baseline.
Patient’s age, gender, body mass index, country of origin and any
interactions were included as needed to produce the best model.
Once a relationship between the total number of comorbidities
and tCAS was found, each comorbidity was then individually
examined for tCAS inﬂuence on it. A logistic regression was run
for each comorbidity modeling its occurrence as a function of tCAS
and age, gender, body mass index and country of origin. Relation-
ships of the different components of the tCAS to the presence of a
given medical condition were preliminarily examined.
Fig. 2. shows the percent of the population at each tCAS score as a function of
having 0 comorbidities, few (1–3), or many (4þ). Those with none or few
comorbidities had the highest percentage of their populations at 0 tCAS and a
rapid dropoff thereafter. In contrast, the 4þ comorbidity category starts with a
small percentage of their population at a 0 tCAS and peaks at a relatively high tCAS
score of 6 before dropping back down.
Coef. RRR Std.
Err.





0.08 0.92 0.03 2.61 0.01 0.14 0.02
Country 0.19 1.21 0.18 1.07 0.28 0.16 0.54
Age 0.02 0.98 0.01 2.49 0.01 0.03 0.00




0.23 1.26 0.03 7.56 0.00 0.17 0.29
Country 0.55 0.58 0.26 2.07 0.04 1.06 0.03
Age 0.01 1.01 0.01 1.14 0.25 0.01 0.03
Gender 0.41 0.66 0.21 1.99 0.05 0.82 0.01
A multinomial logistic regression (above) was used to model the relationship
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The number and percentage of patients reporting each of the
22 medical conditions that occurred in more than 20 individuals
are listed in Table 1. Among the most prominent were allergies,
migraine headache, and head injury (without loss of conscious-
ness), which occurred in 22–37.2% of the patients. These were
followed by hypertension, chronic menstrual irregularities, hy-
pothyroidism, head injury (with loss of consciousness), irritable
bowel syndrome, arthritis, asthma, and other problems occur-
ring in 12–16%.
The distribution of the tCAS are listed and illustrated in Fig. 1.
Nineteen percent had a score of zero, while 47% of the patient
population had a score of 4 or greater. As illustrated in Fig. 2, higher
tCAS were associated with a higher number of medical comorbid-
ities; these were grouped as none, few (1–3), or many (4 or more)
and subjected to multinomial logistic regression which also ac-
counted for age, gender, and country of origin. Signiﬁcant indepen-
dent predictors of having 4þ medical comorbidities as compared to
1–3 included higher tCAS score (the best predictor), being from the
US, and female gender, but not age. Signiﬁcant predictors of having
1–3 medical comorbidities as compared to none included higher
tCAS score, increased age, and female gender, but not country of
origin Fig. 2.
As reported in Table 2, for 11 of the 16 medical conditions
that could be modeled by a logistic regression accounting for
age, gender, and country of origin, the risk of patients having
that speciﬁc comorbidity signiﬁcantly increased as a function
of increasing tCAS. These comorbidities included: allergies,
arthritis, asthma, chronic fatigue syndrome, chronic menstrual
irregularities, ﬁbromyalgia, head injury (without loss of con-
sciousness), hyper- and hypo-tension, irritable bowel syndrome,
and migraine headache.
Table 2 (right column) also shows which parts of the tCAS
produced the best individual component model of the comor-
bidities presence. A history of physical abuse in childhood
remained related to numerous comorbidities, including aller-
gies, chronic fatigue syndrome, head injury (without loss of
consciousness), and hyper- and hypotension. Sexual abuse was
only related to irritable bowel syndrome. Verbal abuse was
related to arthritis and migraine headaches. However, while
the best model was obtained by using the speciﬁed abuse type
listed, one could typically substitute the other types of abuse
with only minor loss in the model’s explanatory power. ParentalFig. 1. shows the distribution of childhood adversity scores with the total
population (n¼890). A tCAS of 0 was the most frequent score (18.7%), but then
tCAS scores of 1–4 occurred with similar frequency (10.5–11.8%). A little over one
third of the population had a tCAS 5 or greater.
between tCAS score and number of comorbidities using 1–3 comorbidities as a
baseline including potential confounds of country of origin, age and gender
(n¼890, likelihood ratio chi-square¼144.27, d.f.¼8, po .000). The top row shows
that having higher tCAS slightly decreased the likelihood of having 0 comorbidities
as opposed to 1–3 (RRR¼0.92).
However, (bottom rows) increasing tCAS score increased the relative risk of having
many (4þ) comorbidities as opposed to few (1–3) by a much larger amount
(RRR¼1.26). Patients from the US (as opposed to Europe) were also more likely to
have many (4þ) comorbidities as compared to few (1–3). Also females were more
likely to be in the higher comorbidity group.history of mood disorder was related to allergies, chronic fatigue
syndrome, and menstrual irregularities; parental history of
substance abuse to arthritis, head injury, and hypotension; and
history of suicidality to ﬁbromyalgia.4. Discussion
As previously reported in the literature, many medical condi-
tions co-occur in adult outpatients with bipolar disorder (Table 1)
whose average age at entry into the Network was just over 40
Table 2
Relationship of total childhood adversity score (tCAS) to 11 medical co-morbidities in adults with bipolar disorder.






n LR P MacFadden’s
pseudo r2
Individual components
Allergies 0.11 11.0 0.02 4.58 0.00 0.06 0.15 884 49.56 0.00 0.04 Physical abuse, Mother mood disorder
Arthritis 0.11 12.0 0.03 3.57 0.00 0.05 0.18 882 127.72 0.00 0.18 Verbal abuse, Mother drug abuse
Asthma 0.10 10.5 0.03 3.26 0.00 0.04 0.16 882 32.21a 0.00 0.05




0.26 30.0 0.11 2.36 0.02 0.04 0.48 500 20.09 0.01 0.03 Verbal abuse, Father mood disorder
Fibromyalgia 0.12 12.9 0.06 2.18 0.03 0.01 0.23 882 48.45 0.00 0.20 Mother suicidal
Head injury Without loss of
consciousness
0.13 13.3 0.03 4.86 0.00 0.07 0.18 885 37.34a 0.00 0.04 Physical abuse, Mother drug abuseb
Hypertension 0.07 6.8 0.03 2.16 0.03 0.01 0.13 867 78.22a 0.00 0.10 Physical abuse
Hypotension 0.18 19.3 0.04 4.86 0.00 0.11 0.25 887 65.73 0.00 0.11 Physical abuse, Mother alcohol
Irritable bowel syndrome 0.07 6.7 0.03 2.15 0.03 0.01 0.12 882 85.27 0.00 0.12 Sexual abuse
Migraine headache 0.11 11.9 0.03 4.48 0.00 0.06 0.16 885 72.20 0.00 0.07 Verbal abuse
Not related to tCAS Score
Diabetes 0.00 0.3 0.06 0.05 0.96 0.12 0.13 884 39.05 0.00 0.16 Age, BMI
Heart disease 0.09 9.8 0.05 2.05 0.04 0.00 0.18 884 41.65 0.00 0.10 Age
Hypoglycemia 0.03 3.4 0.04 0.82 0.41 0.05 0.11 886 32.41 0.00 0.08 Age, Country, Gender
Hyperthyroidism 0.00 0.2 0.06 0.03 0.97  .011 0.11 880 12.56 0.01 0.04 Country, Gender
Kidney disease 0.01 0.5 6.2 0.08 0.93 0.12 0.13 884 13.14 0.07 0.05 Nonsigniﬁcant
Other 0.06 5.8 0.04 1.52 0.13 0.02 0.13 669 11.99 0.10 0.02 Nonsigniﬁcant
This table presents a summary of the inﬂuence of tCAS on each comorbidity. Each comorbidity was modeled with a logistic regression as a function of tCAS score accounting for
potential effects of country, age, gender, body mass index, and their interaction if needed. Comorbidities which could be successfully modeled with no more then minor
speﬁciﬁcation errors (as noted) are presented. This shows overall strength of the model (n, LR, p , r2) and the results of the tCAS factor. The other factors included in the model
are not shown here. The 11 comorbidities listed at the top of the table were successfully modeled, and all increased signiﬁcantly as tCAS increased as indicated in the ﬁfth
column (po(z)). For these comorbidities, the Individual Components (far right column) shows which parts of the tCAS were signiﬁcantly related to a given comorbidity when
each separate component was used in the logistic regression and the best model selected.
In the bottom rows, the tCAS was not related to diabetes, heart disease, hypoglycemia, hyperthyroidism, even though they were well modeled. Kidney disease and ‘‘other’’
produced non-signiﬁcant models, while the other comorbidities (Cancer, Head Injury with Loss of Consciousness, Hypothyroidism, Liver Disease/Hepitatis, and Seizure) could
not be modeled, as speciﬁcation errors were too high to be acceptable.
a a minor speciﬁcation error as determined by a linktest with a hat value between .05 and 1.
b individual components model slightly better and without speciﬁcation error.
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childhood adversity score (tCAS) and the overall number of
medical comorbidities a given patient reported (Fig. 1) and to
11 different medical conditions (Table 2), including allergies,
arthritis, asthma, chronic fatigue syndrome, chronic menstrual
irregularities, ﬁbromyalgia, head injury, hypertension, hypoten-
sion, irritable bowel syndrome, and migraine headaches.
4.1. Mechanisms and implications
Both animal models of childhood adversity and clinical data
have revealed lasting behavioral, endocrinological, and neuro-
chemical consequences of early stressors in part based on epige-
netic mechanisms (Champagne and Meaney, 2001; Meaney and
Szyf, 2005; Roth et al., 2009). Early adversity in animals is
associated with a decrease in hippocampal glucocorticoid recep-
tors based on increased methylation of the GR promoter. These
ﬁndings have been replicated clinically in autopsy studies in
humans (McGowan et al., 2009, 2008), where reduced glucocor-
ticoid receptors and increased methylation of the promoter have
been found in suicide victims with a history of childhood abuse
compared with those without such abuse. Similarly, a substantial
body of evidence indicates that childhood adversity is associated
with increases in inﬂammatory markers and in the risk for being
overweight (Dube et al., 2009; Shonkoff and Garner, 2012), each
of which could also contribute to the vulnerability to many of the
co-occurring medical conditions. Many biological effects asso-
ciated with both stress and affective disorders (increases in
glucocorticoids, inﬂammatory markers, oxidative stress, mito-
chondrial dysfunction, insulin resistance and decreases in neuro-
protective factors) could contribute to increases in allostatic load(Kapczinski et al., 2008; McEwen, 2003, 2004; Post, 2007; Post
et al., 2012) and likewise increase the chance of medical illnesses
and complications.
Scott et al. (2011) reported in a recently published large
international study that both childhood adversity and early-
onset mental disorders (anxiety and depressive disorders) had
independent effects in increasing the risk for diverse chronic
medical conditions in later life, including the six that they
investigated (heart disease, asthma, diabetes, arthritis, chronic
spinal pain, and chronic headache). They also found that a history
of three or more childhood adversities (such as abuse, neglect,
and multiple parental variables) was associated with all six
physical conditions with hazard ratios of 1.44–2.19.
The occurrence of bipolar disorder in the absence of a history
of childhood adversity is associated with a variety of comorbid-
ities, and many of the same mechanisms noted above have been
postulated for such an association. It is clear that there are a
rather extraordinarily large number of years of life expectancy
lost in those with bipolar disorder and other major psychiatric
disorders compared to the general population (Colton and
Manderscheid, 2006; Newcomer Hennekens, 2007; Osby et al.,
2001). The reason for this early demise appears to be highly
attributable to cardiovascular disease, but contributions from
other medical comorbidities and suicide are also apparent to a
lesser extent. The lack of signiﬁcant differences in tCAS in those
with heart disease in this study may in part be due to the relative
low incidence of heart disease (n¼55, 5.8%), likely because of the
relative young age of our population.
The current ﬁndings of an increased burden of medical
comorbidities in those subjects with bipolar disorder who have
higher tCAS scores suggest the importance of discriminating the
R.M. Post et al. / Journal of Affective Disorders 147 (2013) 288–294292differential contributions of bipolar illness itself and that of a
history of childhood adversity on the incidence of various medical
comorbidities and their ultimate impact on functional impair-
ment, disability, and mortality. Since recurrence of stressors,
substances of abuse, and episodes of affective illness each have
been postulated to yield sensitization effects (increased reactivity
upon repetition) as well as cross-sensitization to the others in
part via epigenetic mechanisms (Post, 2010; Post and Kauer-
Sant’Anna, 2010; Post and Miklowitz, 2010; Post et al., 2012), the
ﬁndings further highlight the importance of early intervention
and prevention (Post et al., 2010a, 2010b; Post and Kowatch,
2006). Such early effective treatment might minimize and miti-
gate the effects of childhood adversity, recurrent episodes of
illness, and substances of abuse on subsequent course of bipolar
illness, as well as its numerous comorbidities.
The current study also re-enforces the importance of speciﬁ-
cally focusing on medical comorbidities and their appropriate
treatment in patients with bipolar illness in an effort to decrease
the impact and consequences of such medical conditions on
health, quality of life, and longevity. Many of the medical
comorbidities reported here and in other studies of adults with
bipolar disorder were already present at a disproportionately high
rate in adolescents (age 13–17) with bipolar disorder compared to
a matched control group population (Jerrell et al., 2010). These
included obesity, type II diabetes, dyslipidemia, endocrine dis-
order, organic brain disorder, migraine, epilepsy, cardiovascular
disease, and asthma (Jerrell et al., 2010).
Later in life and in the course of bipolar disorder, the burden of
cardiovascular disease may be even more apparent than that seen
in our study population. A study in Sweden found that bipolar
patients and those in the population at large arrived at the same
age with heart-related complaints, but compared to those in the
general population, the psychiatric patients went on to have
fewer invasive corrective interventions, such as angioplasty and
bypass surgery, thus potentially accounting for their reduced
longevity (Laursen et al., 2009).
We have found that the duration of the interval between the
onset of the ﬁrst episode of bipolar disorder and the ﬁrst
treatment for mania or depression is an independent contributor
to an adverse outcome in adulthood (Post et al., 2010b). This time
to ﬁrst treatment was signiﬁcantly longer in those with a history
of childhood physical or sexual abuse compared with those
without (Post and Leverich, 2006). Thus, increasing recognition
of both the medical and psychiatric difﬁculties that are associated
with a range of childhood adversities may help facilitate earlier
and more effective psychosocial and psychopharmacological
intervention in these children and adolescents who are at risk
for a more adverse course of not only their bipolar disorder but
also the emergence of many other medical conditions as well
(Shonkoff and Garner, 2012).
Social support, early intervention, and other primary and
secondary preventive interventions may also be helpful in
those at highest risk for bipolar disorder (Post and Kowatch,
2006; Post and Leverich, 2006;Post and Miklowitz, 2010; Post and
Post, 2004). Family psycho-education compared with treatment
as usual has consistently been shown to have long-term positive
effects in both adults and adolescents with bipolar disorder
(Colom and Lam, 2005; Miklowitz et al., 2003a, 2003b; Vieta
and Colom, 2004). Part of this education is not only focused on the
symptoms of bipolar disorder but also on enhancing interpersonal
interactions and intra-family communication and minimizing
stressors. Similarly, support by family members, visiting nurse,
or a volunteer may be helpful during periods of parental illness
and minimize the direct or indirect effects of parental diagnosis
on subsequent emergence of medical comorbidities (Eckenrode
et al., 2001; Olds et al., 1999).4.2. Limitations
There are a number of limitations that must be considered in
interperting the ﬁndings of this study. The study was based
entirely on retrospective and self report data. Self-reports of
childhood stressors were based on subjective reports and were
not reconﬁrmed by other informants. However, such self reports
and questionnaire methodology are widely used in epidemiological
and psychiatric studies (Anda et al., 2006; Brown et al., 2005; Felitti
et al., 1998; Garno et al., 2005; Leverich et al., 2002), and some data
suggest that they represent conservative estimates of the actual
occurrence of childhood adversity, which is often forgotten (Hardt
and Rutter, 2004). We also did not have a control group so that
whether any of the relationships described may or may not have
been speciﬁc to this population of bipolar patients is not known.
The classiﬁcation of parental history of psychiatric illness was
also based only on the probands’ reports and not conﬁrmed with
direct interviews of the family members. Again, some investiga-
tors question the reliability of this type of family history, but
others indicate that it has considerable reliability and validity
(Algorta et al., 2011). However, our exclusive use of a parental
history of illness, rather than that of any ﬁrst-degree relative, may
also increase accuracy of reporting.
Another caveat is the utilization of a positive parental history
for psychiatric illness as a reﬂection of potential childhood
adversity. The parental status of active illness versus wellness
during the early years of the proband’s life, which may be an
important factor in the relationship to childhood adversity, was
not obtained. For example, it is known that treating a mother’s
depression to remission is associated with less psychiatric illness
and externalizing disorders in her children compared to mothers
who were similarly diagnosed and treated but did not reach
remission (Wickramaratne et al., 2011). Another confounding
factor would also be the inability to discriminate whether any
contribution of parental psychiatric diagnosis was based on
genetic vulnerability or environmental stressors. The medical
histories of the parents were also not available.
We decided to include these parental measures and construct
a combined tCAS scale in order to closely approximate the
measures of adversity used in other studies in the general
population (Anda et al., 2006; Felitti et al., 1998). Since these
parental variables were indirect and only an indication of poten-
tial childhood adversity, these were rated only as present or
absent for each parent, and not graded according to frequency or
severity, as were the direct reports of verbal, physical, or sexual
abuse, which thus were slightly more heavily weighted in the
tCAS. However, when we used an un-weighted score of just
present or absent for each type of abuse and for either parent
having a psychiatric disorder (or suicide attempt), the results
were highly similar to those seen when the weighted tCAS was
used (analysis not shown). Moreover, in the analysis of the
relationship of different components of the tCAS to individual
comorbidities, both the childhood abuse and parental variables
were found to contribute (Table 2, right column). However, the
precise relationships of different components of the tCAS score
presented in the Table should be considered highly preliminary
and in need of replication as many of the other types of abuse/
adversity would have provided relationships with very little loss
of explanatory power. Certainly a larger N would also give more
conﬁdence about the relationships described. Although our total
childhood adversity scale (tCAS) was similar to the adverse
childhood experience (ACE) scale used by Felitti et al. (1998), it
was not identical. Moreover, the scale has not been independently
validated against other measures in the literature.
Another potential limitation in our study is the reliance on
self-report for garnering patients’ medical history. The study of
R.M. Post et al. / Journal of Affective Disorders 147 (2013) 288–294 293Banks et al. (2006) provides indirect validation of this type of self-
report for medical conditions in 55–65 year old white males. In
that study, self reports of high blood pressure were validated by
actual measures of elevated blood pressure; reports of diabetes by
elevated measures of hemoglobin A1C; inﬂammatory disease
processes by elevated c-reactive protein and ﬁbrinogen, and the
like. Banks et al. (2006) thus concluded that ‘‘Self-reports of
disease are not deceiving us about the reality of the situation’’,
and we would assume our similarly acquired data about one’s
medical conditions would also be reliable especially since they
mirror the incidences of these comorbidities reported in other
studies and populations of bipolar patients. However, the severity
and impact of the medical syndromes listed was not evaluated in
our study. Finally, the neurobiological mechanisms underpinning
the described relationships were not studied and deserve further
exploration, particularly as they might have implications for
therapeutics and prevention.Role of Funding Source
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